subject: Vision Shopsters: Schizophrenia - Drug Pipeline Analysis And Market Forecasts To 2015 [print this page] Summary Summary
The industry analysis specialist, has released a new report, Schizophrenia Drug Pipeline Analysis and Market Forecasts to 2015. The report is an essential source of information and analysis on the global schizophrenia market. The report identifies the key trends shaping and driving the global schizophrenia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global schizophrenia sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalDatas team of industry experts.
Scope
The scope of the report includes:
- Annualized global schizophrenia market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include dopamine serotonin receptor targetters, nicotinic acetylcholine receptors targetters, NK receptors targetters and NMDA receptors targetters.
- Analysis of the current and future market competition in the global schizophrenia market. Key market players covered are AstraZeneca plc, Pfizer Inc., GSK, J&J and Merck & Co.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with schizophrenia.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global schizophrenia market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global schizophrenia market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- Whats the next big thing in the global schizophrenia market landscape? Identify, understand and capitalize.
Companies Mentioned
AstraZeneca, Eli Lilly, Johnson & Johnson , Pfizer, Bristol Myers Squibb , Alexza Pharmaceuticals, Dainippon Sumitomo Pharma, GlaxoSmithKline, Merck & Co, Otsuka Pharmaceutical, Lundbeck, Hoechst Marion Roussel Inc, Titan Pharmaceuticals, Vanda Pharmaceuticals , Schering Plough , Eisai Co Ltd ,
To know more about this report & to buy a copy please visit :
